LOS ANGELES, March 30, 2020 /PRNewswire/ -- ImaginAb Inc., a leading clinical stage immuno-oncology imaging company, today announced it has signed a multi-year non-exclusive license agreement with AstraZeneca. Under the terms of the agreement, ImaginAb's CD8 ImmunoPET technology will be...
from PR Newswire: https://ift.tt/3bCdD1K
No comments:
Post a Comment